1. Home
  2. CODA vs WHWK Comparison

CODA vs WHWK Comparison

Compare CODA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$13.71

Market Cap

155.4M

Sector

Industrials

ML Signal

HOLD

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$3.96

Market Cap

95.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
WHWK
Founded
1994
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.4M
95.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
CODA
WHWK
Price
$13.71
$3.96
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
331.6K
143.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
15.62
N/A
EPS
0.08
N/A
Revenue
$20,316,161.00
N/A
Revenue This Year
$16.42
N/A
Revenue Next Year
$14.43
N/A
P/E Ratio
$160.69
N/A
Revenue Growth
4.98
N/A
52 Week Low
$5.76
$1.39
52 Week High
$18.00
$4.40

Technical Indicators

Market Signals
Indicator
CODA
WHWK
Relative Strength Index (RSI) 50.29 67.87
Support Level $13.01 $1.84
Resistance Level $14.89 $4.40
Average True Range (ATR) 1.23 0.28
MACD -0.22 0.03
Stochastic Oscillator 19.36 66.08

Price Performance

Historical Comparison
CODA
WHWK

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Share on Social Networks: